Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1634 1641 1644
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18004550 | Anti-Notch2 Antibodies and Methods of Use | Final Rejection | Genentech, Inc. |
| 18035054 | METHODS FOR ADMINISTERING A BCMAXCD3 BINDING MOLECULE | Non-Final OA | AMGEN INC. |
| 19271944 | COMPOSITIONS AND METHODS FOR DETECTING AND REGULATING FIBRONECTIN-INTEGRIN INTERACTION AND SIGNALING | Non-Final OA | Georgia Tech Research Corporation |
| 18330903 | ANTIBODIES TO HUMAN COMPLEMENT FACTOR C2b AND METHODS OF USE | Non-Final OA | ARGENX BV |
| 19187625 | BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS | Final Rejection | MOONLAKE IMMUNOTHERAPEUTICS AG |
| 17759388 | ANTI-avB8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE | Non-Final OA | MEDIMMUNE LIMITED |
| 17596699 | METHODS FOR TREATING NEOINTIMAL HYPERPLASIA USING F11R/JAM-A INHIBITORS | Final Rejection | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK |
| 18614952 | MAP44 POLYPEPTIDES AND CONSTRUCTS BASED ON NATURAL ANTIBODIES AND USES THEREOF | Non-Final OA | The Regents of the University of Colorado, A Body Corporate |
| 18253280 | STEROID SPARING | Non-Final OA | ASTRAZENECA AB |
| 18549665 | USES OF CD79B ANTIBODIES FOR AUTOIMMUNE THERAPEUTIC APPLICATIONS | Non-Final OA | JANSSEN BIOTECH, INC. |
| 17980149 | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody | Final Rejection | Janssen Biotech, Inc. |
| 17655541 | METHODS FOR THE TREATMENT OF CHRONIC POUCHITIS | Non-Final OA | Millennium Pharmaceuticals, Inc. |
| 16608895 | METHOD OF TREATING PEDIATRIC DISORDERS | Non-Final OA | Millennium Pharmaceuticals, Inc. |
| 18459995 | ANTIBODIES, COMBINATIONS COMPRISING ANTIBODIES, BIOMARKERS, USES & METHODS | Final Rejection | KYMAB LIMITED |
| 18364906 | ANTIBODIES, USES & METHODS | Final Rejection | Kymab Limited |
| 18535781 | VEDOLIZUMAB FOR THE TREATMENT OF FISTULIZING CROHN'S DISEASE | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18454015 | ANTI-CD47 ANTIBODIES AND USES THEREOF | Non-Final OA | Lepu Biopharma Co., Ltd. |
| 18277911 | VARIANT FC DOMAINS AND USES THEREOF | Non-Final OA | Cidara Therapeutics, Inc. |
| 18218996 | Sialylated Glycoproteins | Non-Final OA | Momenta Pharmaceuticals, Inc. |
| 17528364 | METHOD OF TREATING CANCER | Non-Final OA | HIRATA CORPORATION |
| 18450022 | ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) | Non-Final OA | UNIVERSITY OF RIJEKA FACULTY OF MEDICINE |
| 18134844 | NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWIS A | Non-Final OA | BioNTech SE |
| 18039251 | ANTI-ANGPTL3 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND PREPARATION METHOD AND USE THEREOF | Non-Final OA | CHILDREN'S HOSPITAL OF FUDAN UNIVERSITY |
| 18320912 | COMPOSITIONS, METHODS AND/OR KITS COMPRISING A RECOMBINANT HUMAN CD38-EXTRACELLULAR DOMAIN | Final Rejection | GRIFOLS DIAGNOSTIC SOLUTIONS INC. |
| 18031731 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | Non-Final OA | KEYMED BIOSCIENCES CO., LTD |
| 18028702 | ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS SPECIFICALLY BINDING TO GREMLIN-1 AND USES THEREOF | Non-Final OA | KANTONSSPITAL ST. GALLEN |
| 18170890 | ANTIBODIES RECOGNIZING TAU | Non-Final OA | Prothena Biosciences Limited |
| 17791681 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | Final Rejection | Dyne Therapeutics, Inc. |
| 17919002 | 28 KDA GST PROTEINS FROM SCHISTOSOMA FOR THE TREATMENT OF VASCULITIS | Non-Final OA | PAR'IMMUNE SAS |
| 17788539 | CD 163 ANTIBODIES OR BINDING PROTEINS | Final Rejection | ECO ANIMAL HEALTH LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy